Profile data is unavailable for this security.
About the company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
- Revenue in USD (TTM)4.91m
- Net income in USD-13.32m
- Incorporated1997
- Employees20.00
- LocationPlus Therapeutics Inc4200 Marathon Blvd Ste 200AUSTIN 78756-3433United StatesUSA
- Phone+1 (858) 458-0900
- Fax+1 (302) 636-5454
- Websitehttp://www.plustherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azitra Inc | 686.00k | -12.64m | 6.48m | 10.00 | -- | 0.934 | -- | 9.44 | -2.99 | -2.99 | 0.0713 | 0.2408 | 0.1117 | -- | 4.88 | 68,600.00 | -183.73 | -- | -266.83 | -- | -- | -- | -1,644.87 | -- | -- | -45.86 | 0.0138 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| CV Sciences Inc | 16.00m | 3.10m | 6.48m | 42.00 | 1.92 | 2.21 | 1.94 | 0.4049 | 0.0206 | 0.0206 | 0.104 | 0.018 | 1.46 | 1.46 | 26.74 | 381,047.60 | 28.28 | -43.42 | 247.47 | -77.75 | 44.27 | 51.81 | 19.38 | -45.68 | 0.3733 | 13.68 | 0.0805 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| Creative Medical Technology Holdings Inc | 9.00k | -5.29m | 6.53m | 4.00 | -- | 0.6388 | -- | 725.04 | -3.76 | -3.76 | 0.0064 | 7.53 | 0.0006 | 0.4291 | -- | 2,250.00 | -35.36 | -110.00 | -40.34 | -- | 60.00 | 65.82 | -58,739.67 | -7,961.14 | 27.64 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -6.59m | 6.53m | 8.00 | -- | 1.54 | -- | -- | -0.441 | -0.441 | 0.00 | 0.2524 | 0.00 | -- | -- | 0.00 | -90.28 | -- | -104.75 | -- | -- | -- | -- | -- | -- | -49.56 | 0.1527 | -- | -- | -- | -112.71 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -415.48k | 6.59m | 0.00 | -- | 15.09 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0013 | 0.00 | -- | -- | -- | -88.08 | -696.88 | -96.94 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Kineta Inc | 5.44m | -14.10m | 6.80m | 11.00 | -- | 2.23 | -- | 1.25 | -1.43 | -1.43 | 0.5297 | 0.278 | 0.3927 | -- | -- | 494,727.30 | -101.57 | -66.16 | -318.39 | -86.61 | -- | -- | -258.65 | -854.74 | -- | -1,310.25 | 0.2011 | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -17.46m | 6.81m | 7.00 | -- | 1.31 | -- | -- | -8.15 | -8.15 | 0.00 | 0.7142 | 0.00 | -- | -- | 0.00 | -144.99 | -104.94 | -207.98 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| eFFECTOR Therapeutics Inc | 0.00 | -35.81m | 6.82m | 14.00 | -- | -- | -- | -- | -17.11 | -17.11 | 0.00 | -1.94 | 0.00 | -- | -- | 0.00 | -144.34 | -- | -- | -- | -- | -- | -- | -- | -- | -17.38 | 1.43 | -- | -100.00 | -- | -58.00 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 4.91m | -13.32m | 6.84m | 20.00 | -- | -- | -- | 1.39 | -4.51 | -4.51 | 1.57 | -0.3033 | 0.2787 | -- | -- | 245,650.00 | -75.54 | -59.18 | -210.10 | -133.04 | -- | -- | -271.04 | -470.45 | -- | -- | 1.51 | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 6.86m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Clever Leaves Holdings Inc | 17.42m | -19.80m | 6.90m | 296.00 | -- | 0.2804 | -- | 0.396 | -12.57 | -11.38 | 11.11 | 14.02 | 0.418 | 1.69 | 11.03 | 58,841.21 | -47.51 | -23.20 | -58.14 | -26.55 | 37.64 | -- | -113.66 | -207.52 | 1.63 | -3.70 | 0.0479 | -- | 6.14 | -- | 47.63 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -7.00m | 6.93m | 4.00 | -- | 0.6966 | -- | -- | -5.83 | -4.17 | 0.00 | 2.45 | 0.00 | -- | -- | 0.00 | -133.76 | -182.35 | -174.49 | -235.45 | -- | -- | -- | -- | -- | -55.50 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| SYBLEU Inc | 11.70k | -307.88k | 6.96m | -- | -- | -- | -- | 594.72 | -0.0293 | -0.0293 | 0.0011 | -0.0367 | 0.0641 | -- | -- | -- | -168.63 | -- | -- | -- | -- | -- | -2,631.45 | -- | -- | -8.48 | 4.96 | -- | 0.00 | -- | 26.51 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -7.71m | 6.97m | 5.00 | -- | 0.1311 | -- | -- | -33.51 | -33.51 | 0.00 | 27.15 | 0.00 | -- | -- | 0.00 | -102.20 | -199.16 | -159.72 | -285.64 | -- | -- | -- | -- | -- | -82.13 | 0.0583 | -- | -- | -- | 30.21 | -- | -- | -- |
| Trevena Inc | 3.13m | -40.29m | 6.98m | 23.00 | -- | -- | -- | 2.23 | -3.16 | -3.16 | 0.2611 | -0.4429 | 0.07 | 3.69 | -- | 135,869.60 | -90.25 | -55.93 | -110.38 | -66.35 | 46.56 | -- | -1,289.25 | -3,134.41 | 4.66 | -15.43 | 1.33 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| AiXin Life International Inc | 4.09m | -2.09m | 7.00m | 207.00 | -- | -- | -- | 1.71 | -0.0836 | -0.0836 | 0.1636 | -0.0765 | 0.8268 | 5.43 | 10.02 | 19,757.49 | -42.27 | -16.93 | -- | -34.54 | 16.25 | 48.13 | -51.12 | -36.96 | 0.1515 | -- | -- | -- | 51.00 | 58.08 | 67.18 | -- | 194.59 | -- |
Data as of Apr 25 2024. Currency figures normalised to Plus Therapeutics Inc's reporting currency: US Dollar USD
3.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2023 | 33.00k | 0.77% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 32.54k | 0.76% |
| Geode Capital Management LLCas of 31 Dec 2023 | 26.54k | 0.62% |
| Citadel Securities LLCas of 31 Dec 2023 | 16.84k | 0.39% |
| Ground Swell Capital LLCas of 31 Dec 2023 | 14.30k | 0.33% |
| UBS Securities LLCas of 31 Dec 2023 | 8.90k | 0.21% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 6.96k | 0.16% |
| Tower Research Capital LLCas of 31 Dec 2023 | 572.00 | 0.01% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2023 | 133.00 | 0.00% |
| FSC Securities Corp.as of 30 Sep 2023 | 133.00 | 0.00% |
More ▼
Data from 30 Sep 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
